Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

Laurent Azoulay, Hui Yin, Kristian B Filion, Jonathan Assayag, Agnieszka Majdan, Michael N Pollak and Samy Suissa
BMJ: British Medical Journal
Vol. 344, No. 7862 (23 June 2012), p. 15
Published by: BMJ
Stable URL: http://www.jstor.org/stable/23235724
Page Count: 1
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Preview not available

Abstract

STUDY QUESTION Is the use of pioglitazone associated with an increased risk of incident bladder cancer in people with type 2 diabetes? SUMMARY ANSWER The use of pioglitazone is associated with an increased risk of bladder cancer. The risk is greatest after more than 24 months of use and at cumulative dosages above 28 000 mg. WHAT IS KNOWN AND WHAT THIS PAPER ADDS This study provides additional evidence that the use of pioglitazone is associated with an increased risk of bladder cancer.

Page Thumbnails

  • Thumbnail: Page 
15
    15